The Canada Antidepressants market size stood at around USD XX billion in 2019 and is projected to reach USD XX billion by 2028, exhibiting a CAGR of XX% during the forecast period.
Mental illness indirectly affects all Canadians at some time through a family member, friend, or colleague. In any given year, 1 in 5 people in Canada will personally experience a mental health problem or illness. Mental illness affects people of all ages, education, income levels, and cultures. Approximately 8% of adults will experience major depression at some time in their lives. About 1% of Canadians will experience bipolar disorder (or “manic depression”). 70% of mental health problems have their onset during childhood or adolescence. Young people aged 15 to 24 are more likely to experience mental illness or substance use disorders than any other age group. Antidepressant prescribing rates continue to increase in Canada, although the prescribing patterns have changed over the past few years. The wide use of expensive antidepressants and those with weak clinical evidence raises concerns regarding the rational use of antidepressants.
Growing public awareness about depression, changes in patients’ attitudes, the expansion of therapeutic indications, a complex interplay of genetic, biological, personality, and environmental factors, and the impact of commercial interests are the primary drivers for the growth of the Anti-depressants market in Canada. In clinical practice, antidepressants are prescribed for many conditions other than depression, such as anxiety, sleeping disorders, psychosis, and neuropathic pain. This has led to concerns that antidepressants are being overprescribed. Also, with the accelerated development of Canada, various social contradictions have become prominent, people’s life pressure has increased, and the incidence of depression has continued to rise. The rapid development of the depression medication market and product declarations have shown a prosperous trend in the Canadian market.